HCCI research on shoppable services was mentioned in an article written by the LA Times. From the article: "By one estimate by the Health Care Cost Institute, just 7% of total healthcare spending for Americans with job-based coverage was on medical services that could be considered 'shoppable' because the service required an out-of-pocket payment and the procedure could be researche...
HCCI's research on median in-network rates was recently featured in a Health Affairs blog post on surprise billing. From the blog: "Most importantly, Congress should establish a locally based benchmark to determine the amount an insurer would be required to pay a provider for a surprise bill. Ideally, we'd set the benchmark at some multiple (for example 125 percent) of what Medicare pays to ...
HCCI's research on insulin prices was mentioned in a CNBC report. From the article: "The Centers for Disease Control and Prevention estimates more than 30 million Americans have diabetes. The annual cost of insulin for people with Type 1 diabetes in the U.S. nearly doubled from 2012 to 2016 to $5,700 from $2,900, according to an analysis by the nonprofit Health Care Cost Institute. Eli L...
HCCI recently provided cost information for iron infusions for an NPR article. From the article: "An analysis of private insurance claims conducted by the Health Care Cost Institute, an independent research group funded by insurers, found that in 2017, private health plans paid $4,316 per visit, on average, if a patient received Injectafer infusions. Feraheme, the next most expensive in...
Changes in opioid utilization correlated with state-level policy changes aimed at decreasing opioid prescription rates. Previous research by HCCI illustrated that national opioid utilization in pills per person fell 27% between the years of 2008 and 2017, driven by declines in the use of hydrocodone (Vicodin). In addition to giving insight into prescription opioid utilization by the commercially i...
